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Abstract
Background: Early diagnosis in patients with systemic lupus erythematosus (SLE), which is based on the knowledge of the variability of the initial disease 
manifestation, followed by prompt initiation of basic therapy is essential for a favorable prognosis in these patients. Thus, the determination of early 
manifestations of the disease in patients with lupus was the main objective of this study.
Material and methods: This present descriptive study included 68 patients with early SLE – the disease duration being of up to 2 years after the diagnosis. 
The evaluation of the characteristics of the disease was performed by a questionnaire developed by this study, which included the clinical and paraclinical 
examination. Statistical data processing was performed via Excel program. 
Results: The analysis of the results on early manifestations of the disease revealed the high frequency of joint involvement in 64.7%, photosensitivity and 
malar rash – in 58.82% and 32.35%, respectively, and oral ulcers and alopecia were found in about 1/4 cases. The signs detected, but omitted from the 
criteria with increased occurrence were represented by fatigue in 42.64% of cases, fever – 29.41%, myalgia and Raynaud’s syndrome in 20.58% of patients. 
It should be noted that the first lupus-associated manifestations were noticed 1-4 years prior to diagnosis. 
Conclusions: Top early manifestations in patients enrolled in the current study included arthralgia, photosensitivity and fatigue. These symptoms were 
followed by malar rash and fever. 
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Introduction
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease with a wide spectrum of clinical and im-
munological abnormalities of unknown etiology, which 
develops on the base of imperfect genetically determined 
immunoregulatory processes, associated with the overpro-
duction of autoantibodies. Genetic, environmental and so-
ciodemographic factors play important roles in the patho-
genesis and expression of this disease. This multiplicity of 
etiological factors could explain the variability of disease 
manifestations observed, not only between individuals, but 
also between ethnic groups [1, 2]. SLE is a pathology that af-
fects people of different ages, races, origins, gender; mostly 
women of childbearing age are affected, in 83-97% of cases. 
The systematic literature review (Rees, 2017) of the global 
incidence of SLE reported the highest estimated incidence 
and prevalence of SLE which were found in North America 
(23.2/100 000 person-year and 241/100 000 people, respec-
tively). The lowest incidence of SLE was reported in Africa 
and Ukraine (0.3/100 000 person-year), and the lowest 
prevalence was found in Northern Australia (zero cases in a 
sample of 847 people) [3]. 
Over the last few decades, SLE has changed its expres-
sion, which was reflected in the revision of the disease clas-
sification criteria. The first SLE classification criteria were 
developed by the American College of Rheumatology in 
1971 by the Cohen A.S. Working Group, and were subse-
quently revised in 1982 (E. Tan et al.). In the light of the 
new findings , that is the presence and association of an-
tiphospholipid antibodies in patients with SLE, the 1982 cri-
teria were revised and new criteria were approved in 1997 
(Hochberg M.C.). The latest criteria from 2012 – SLICC 
(Systemic Lupus International Collaborating Clinic) have 
been extended due to skin manifestations and strengthen-
ing of immunological indices by the complement fractions 
C3, C4 [4].
Systemic lupus erythematosus, however, remains an ac-
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tual research domain over the last years, especially the early 
stage of the disease. Over the last decade, SLE has changed 
due to improved classification criteria and, last but not least, 
due to the early use and administration of aggressive treat-
ment [5]. The clinical onset depends on several risk fac-
tors, including gender, age, ethnicity, geographic area, etc. 
Specific and non-specific clinical events, which occur dur-
ing the inception and evolution of SLE, have a high vari-
ability. Thus, the vector of the research in the field is being 
directed for a few years at studying the clinical and immu-
nological manifestations of onset of SLE, as well as in the 
first years of the disease [6-9]. This trend can be explained 
by the attempt of researchers to further improve the crite-
ria for classifying the disease, increasing the sensitivity and 
specificity of these criteria, to reduce the time of diagnosis 
of the disease from the onset of the first symptom associated 
with lupus erythematozus to clinical diagnosis.
The evolution of SLE is characterized by the comple- 
xity and uncertainty of the disease diagnosis, which can lead 
to considerable delays between the initial manifestations of 
the disease, establishing a diagnosis and initiating appropri-
ate medical treatment. Delayed or lack of treatment may in-
crease the likelihood of organic damage due to high disease 
activity. Thus, in earlier diagnosed patients, the inflamma-
tory disease can be treated earlier and organic damage could 
be minimized [10].
Thus, the necessary time for diagnosis of the disease ex-
presses the first principle in the proper management of the 
disease, while the reduction of the diagnosis period reveals 
the importance of early therapeutic intervention. 
Based on the aforementioned, this research study was 
oriented towards determining the manifestations of early 
SLE, which is the most important factor for a prompt esta-
blishment of  the disease  diagnosis. The purpose  of the 
study was to evaluate early manifestations of the disease in 
patients with SLE within the study group.
Material and methods
A cross-sectional study was conducted at the Department 
of Internal Medicine within Nicolae Testemitanu State 
University of Medicine and Pharmacy of the Republic of 
Moldova, and at the Rheumatology Department of the 
Institute of Cardiology. The patients were enrolled from June 
2016 to May 2019, according to the accepted approval of the 
Research Ethics Committee (No 66 of 16.06.2016). The re-
search included 68 patients who were selected according to 
SLICC classification criteria for systemic lupus erythemato-
sus, validated in 2012. The SLICC 2012 classification criteria 
consist of 11 points, which form two compartments: clinical 
and immunological. The diagnosis is established if at least 
four criteria are included, one clinical and one immunologi-
cal, except for renal damage confirmed by renal biopsy as-
sociated with an immunological criterion. The research in-
cluded subjects over 18 years old, who signed an informed 
consent for study participation. Exclusion criteria included 
other confirmed rheumatologic diseases as well as patient’s 
refusal. The clinical and demographic data, as well as infor-
mation about disease characteristics were collected accord-
ing to a file prepared within the present study. The question-
naire included information on clinical and demographic 
data – gender, place of residence, marital status, age at onset 
and duration of the disease. The special investigation was 
performed in order to highlight the symptoms and signs at 
the onset of the disease, which represented the criteria for 
the established diagnosis. The model used within the pres-
ent study was based on literature analysis, and presented as 
early signs of lupus, which was completed together with the 
subject. Moreover, every patient was asked about the time 
of symptom onset, before and after the diagnosis of SLE was 
established. 
The obtained results were analyzed via the Microsoft 
Office Excel program. The structure and dynamics of the re-
searched phenomena were examined using statistical meth-
ods with the assessment of arithmetic means (M), standard 
deviations (SD) and confidence interval (CI). The statistical 
comparison of the data and the determination of the signifi-
cance test allowed the assessment of the differences between 
the mean and percentage values. The differences between 
the mean values of the studied parameters were estimated 
using the t-Student criterion.
Results
A performed cross-sectional study included 68 consecu-
tive patients with early SLE, admitted to the Rheumatology 
Department at the Institute of Cardiology, the duration of 
the disease lasted up to 2 years after being diagnosed.The 
demographic data of the study lot is presented in the table 1.
Table 1
Demographic indices in the investigated  
sample (no = 68)
Parameters Patients, No %
Gender:
Women
Men
65 
3 
95.59 
4.41
Place of residence: 
Rural
Urban
36 
32 
52.94
47.06
Marital status:
Married
Divorced
Widower
Bachelor
36 
14 
4 
14 
52.94
20.59
 5.88
20.59
The data presented in the table 1 revealed the predomi-
nance of women (95.59%) in the study group, with a female 
to male ratio of 22:1. According to the place of residence, 
patients from rural areas evidenced their light preponder-
ance in the space. After the segregation of the patients’ mari-
tal status we attested that at the time of research 36 (52.94%) 
subjects lived with families being married, 20.59% of cases 
were divorced or not married yet, and 5.88% of the subjects 
included in the study were widows/widowers.
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Further reseasch assessed the age characteristics at the 
time of research and at the onset of the disease in patients 
included in the study, as well as the mean duration of the 
disease and the time from the first symptoms to diagnosis.
Table 2
Characteristics of variables in the research group
Parameters
Mean 
value±SD
Min V 
Max V
Mean age at the time of the research, 
years
39.6±15.0 20-73
Mean age at the time of the disease 
onset, years
38.47±14.88 20-67
Mean duration of the disease, months 12.42±8.70 0.5-24
Time from the disease onset to the SLE 
diagnosis confirmation, months
7.08±8.22 1-47
SLICC cumulative criteria number, abs.nr. 7.32±2.06 4-12
The data presented in the table 2, concluded that patients 
with early SLE had a mean age of 39.6 years, ranging be-
tween 20 and 73 years, while the mean age at the disease on-
set was 38.47 years. Concerning the duration of the disease, 
it varied from 1 to 24 months, as the definition of the early 
SLE, the mean duration was 12.42 months. The time from 
the first symptoms, claimed by the patient, until the con-
firmation of the SLE diagnosis varied from 1 to 47 months, 
with the mean time of the disease diagnosis of 7 months. 
The cumulative number of SLICC based on 2012 classifica-
tion criteria at study entry was in average 7.3, with the high-
est number of 12 criteria. 
In order to analyze and describe the study group, the 
time from the onset of the first symptoms to the referral to 
the doctor and later to diagnosis confirmation of systemic 
lupus erythematosus was identified.
Table 3
Quantification of the disease diagnosis term
Parameters
Mean 
value±SD
Min V 
Max V
Time from the disease onset to referral 
to healthcare (months)
4.81±6.57 0.25-37
Time from referral to healthcare to dia-
gnosis confirmation (months)
2.27±2.1 0.75-10
Patients referred to the doctor on average at 4.81 
months, with one or more symptoms that were later related 
to systemic lupus erythematosus (tab. 3). The shortest time 
was one week, the earliest manifestations being fever and 
edema. Patients with clinical signs, such as malar rash, ar-
thritis and serositis referred to the doctor one month after 
the symptoms appeared. In addition to these manifesta-
tions, many patients experienced a marked fatigue at the 
time of disease onset, which they thought was not a reason 
for referring to healthcare. Patients who had photosensitiv-
ity, malar rash and  joint pain as first manifestations referred 
to medical healthcare starting from 0.25 to 37 months. Thus, 
regarding the time of diagnosis confirmation from the first 
medical referral, the mean time of diagnosis established was 
2.27 months, the shortest term being 3 weeks. 
The complexity of the autoimmune process and the dif-
ficulty of diagnosing early SLE, due to the insufficiency of 
diagnostic criteria, can lead to considerable delays between 
the onset of the disease and the time of diagnosis. In fact, 
patients from the study group developed specific manifesta-
tions of lupus at the onset of the disease, stated in the dis-
ease classification criteria, as well as pathological changes 
omitted from the classification criteria, which however 
deserve special attention in case of early diagnosis of the 
disease. Further, the study identified the early signs of the 
disease by calculating their frequency in the study subjects 
(tab. 4).
Table 4
Clinical signs in patients before referral to primary care
SLE signs
Patients No=68
No % 95% CI
Malar rash 22 32.35 0.22-0.44
Fotosensitivity 40 58.82 0.46-0.69
Maculopapular rash 4 5.88 0.02-0.14
Discoid rash 2 2.94 0.008-0.01
Oral/nasal ulcers 18 26.47 0.17-0.38
Difuse alopecia (non-cicatriceal) 18 26.47 0.17-0.38
Arthritis/arthralgia 44 64.70 0.52-0.75
Serositis: Pleuritis
Pericarditis
6
2
8.82
2.94
0.04-0.17
0.008-0.01
Lupus nephritis (nephrotic/nephritic 
syndrom)
4 5.88 0.02-0.14
CNS involvement: Polineuropathy 4 5.88 0.02-0.14
Headache 8 11.76 0.06-0.21
Depression 10 14.70 0.008-0.25
Hemolitic anemia 1 1.47 0.02-0.07
Fever 20 29.41 0.19-0.41
Fatigue 29 42.64 0.31-0.54
Weight loss 10 14.70 0.08-0.25
Limphadenopathy 9 13.23 0.7-0.23
Myalgia 14 20.58 0.12-0.31
Livedo reticularis 10 14.70 0.08-0.25
Sjogren syndrom 8 11.76 0.06-0.21
Raynaud syndrom 14 20.58 0.12-0.31
Vascular thrombosis 2 2.94 0.008-0.1
Spontaneous pregrancy loss, n-65 3 4.62 0.001-0.12
The material presented in table 4 resume the early signs 
that can be associated with lupus. Therefore, the clinical pic-
ture from the onset of the disease until the doctor’s assess-
ment was determined in 64.70% of cases related to joint in-
volvement according to the classification criteria. It should 
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be noted that joint pain without synovitis or morning stiff-
ness, was most commonly reported, accounting for 80.88% 
of patients.
The skin involvement manifested by photosensitivity and 
malar rash was registered in 58.82% and 32.35% of cases, re-
spectively; followed by oral and / or nasal ulcers and diffuse 
non-scarring alopecia in 26.47% of cases. Maculopapular 
and discoidal rash were rare skin manifestations in the early 
period and were reported in 5.88% and 2.94% of patients. 
The characteristic SLE signs, however not occurring at the 
onset of the disease were serous pleurisy and pericarditis 
(8.82% and 2.94%, respectively). Regarding renal impair-
ment, it was manifested by nephrotic or nephritic syndrome 
and was present in 5.88% of cases. The involvement of the 
nervous system, which is a part of the SLICC classification 
criteria, was characterized by polyneuropathy, in 5.88% of 
cases. Hemolytic anemia, which is an early manifestation 
of lupus, has been rarely reported, only in one patient viz. 
1.74% of cases. 
Carefully analysis identified signs related to systemic lu-
pus erythematosus in the early stages of the disease, though 
not included in the 2012 SLICC classification criteria. 
Fatigue, one of the most exhausting symptoms in patients 
with SLE was reported in 29 (42.64%) subjects from our 
study lot. Another important constitutional sign was fever 
in the absence of infection, estimated in 20 (29.41%) cases. 
Weight loss of more than 5-10% of body weight in the last 6 
months or a decrease of more than 5 kg in the last month, in 
the absence of other causes, as an early symptom of the dis-
ease, was reported in 14.70% of cases. Another early mani-
festation-myalgia, was reported as pain or muscle weakness 
in the absence of obvious causes in 14 (20.58%) patients. 
The presence of lymphadenopathy was characterized by the 
increase in size of more than 5 cm of the lymph nodes in 
the cervical, axillary or inguinal areas, in the absence of in-
fectious or malignant process, being detected in 9 (13.23%) 
cases. Neurological manifestations, such as depression and 
headache, which are not included in classification crite-
ria of the disease, were reported in 10 (14.70%) and eight 
(11.76%) subjects, respectively. The involvement of periphe-
ral vessels at the onset, manifested by Raynaud’s Syndrome 
and / or reticular livedo, was found in 14 – 20.58% and 10 – 
14.70% of patients, respectively. Venous thrombosis was an 
early manifestation of the disease in 2.94% of cases. Sjogren’s 
syndrome, one of the early signs of the disease, was present 
in 8 (11.76%) patients as the first symptom of the disease. 
Spontaneous abortion, which is an important manifestation 
at the onset of the disease among young patients, occurred 
in 3 patients out of 65 (4.62%).
Following the idea of early signs, this present study sepa-
rated the top most common manifestations of systemic lu-
pus erythematosus (fig. 1).
The first signs attributed to lupus, at the time of refer-
ral corresponded to the 2012 SLICC classification criteria, 
as well as included the constitutional ones, which were not 
provided by these criteria. In fact, as shown in figure above, 
the top three early manifestations were arthralgia, photo-
sensitivity and fatigue, while the top five variables were fol-
lowed by malar rash and fever.
Hypothetically, the study was oriented towards the clini-
cal signs preceding the diagnosis of SLE and their chrono-
logical stratification. The earliest SLE-associated clinical 
manifestations were recorded 1-3 and even 4-5 years before 
the diagnosis of the disease. From the first year until the es-
tablished diagnosis,  68 patients presented 188 criteria, each 
patient had 2.64 clinical signs, 2 years before patients had 
104 (1.52), 3 years before – 88 (1.29) signs and 4-5 years 
before the diagnosis was established 39 (0.57) criteria were 
recorded for patients with early SLE. A year prior to estab-
lishing the diagnosis was characterized by presence of at 
least 3-4 signs of lupus in the same patient, which led to the 
motivation of their immunological research. Thus, transient 
arthralgia, seasonal photosensitivity and episodic fever were 
the 4-5 year preceding signs of the diagnosis; at the same 
time, 3 years before, malarial rash, weight loss and leuko-
penia up to 4.0 x 109 occurred. Two years before the diag-
nosis, the patients’ signs were characterized by installation 
of serositis, oral ulcers and thrombocytopenia, increased 
ESR, anemia and false positive MRS. The year preceding the 
diagnosis was characterized by installation of several signs, 
including the laboratory ones.
Moreover, the supplementation of clinical variables with 
laboratory research could have accelerated the establish-
ment of the diagnosis of lupus, which could have been es-
tablished at least 2 years before, based on clinical picture 
and in compliance with four diagnostic criteria.
Furthermore, the study examined the laboratory indices 
by analyzing the hematological parameters at the time of 
the research in the context of the disease classification cri-
teria. Thus, the most frequent hematological manifestation 
in early disease was leucopenia in 29.41% of cases, followed 
by anemia in 20.59% of subjects. Thrombocytopenia and 
lymphopenia were found in 19.12% and 16.18% of cases, 
respectively. 
The immunological criteria analysis distinguished that 
the most common were the antinuclear antibodies (ANA) 
(92.65% of cases) and anti-dsDNA (91.17%). Another im-
munological criterion in early lupus patients was the in-
creased incidence of low titers of complement fractions C3 
and C4, identified in 58.82%. The presence of antiphospho-
lipid antibodies was characterized by a higher frequency of 
lupus anticoagulant – 17.64%, followed by anti-CL antibod-
ies and anti-β2GP1 antibodies, found in only 5.88% and 
Fig. 1.  Top early manifestations of SLE
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2.94% of cases, respectively. As regarding the anti-Smith an-
tibodies and the Coombs test, these were present in 11.76% 
and 14.70% of patients, respectively.
Consequently, the most common paraclinical mani-
festations, including the immunological ones, in the ear-
ly period of the disease were the anti-dsDNA (91.17%), 
ANA (79.41%), low titer of complement fractions (C3, C4) 
(58.82%), as well as leukopenia (29.41%).
Discussion
The present study, described the frequency and char-
acteristics of the major SLE clinical manifestations and the 
time of the disease diagnosis in patients from the Republic 
of Moldova. The important fact is that the time between the 
onset of symptoms and established diagnosis in last decades 
has been shortened [2, 5, 11], and yet suggests that it is not 
short enough and more efforts should be made to establish 
the diagnosis of SLE even faster [12]. For patients diagnosed 
with SLE before 1980, the mean time between the onset and 
established diagnosis was 59 months, which subsequently 
decreased to 28 months for patients diagnosed between 
1980 and 1989, and to 20 months for patients diagnosed be-
tween 1990 and 2010 [11, 13]. ANA testing credited differ-
ences in the diagnosis delay before 1980th and after 1980th. 
Some authors suggest that the average time to disease diag-
noses after the 2000s has been reduced to 9 months [14]. The 
present study data showed that the average time for disease 
diagnosis was 7.08 months. These results could be explained 
by improving the diagnosis, by providing a wider use of im-
munological criteria, which are more extensive and acces-
sible to perform, as well as medical assistance provided by 
the highly qualified doctors and dissemination of informa-
tion through reports presented at conferences and working 
groups or multidisciplinary and continuing medical educa-
tion. The main cause of the shortest diagnosis, lasting up till 
one month prior to primary healthcare was the addressabil-
ity of the patient presenting such symptoms like fever, ede-
ma, malar rash and arthritis. The longest period requiring 
medical referral from the symptom onset lasted 37 months, 
and the patients experienced their first manifestations as 
photosensitivity, malarial rash or non-swollen joint pain. 
Thus, as regarding the time of diagnosis confirmation from 
the time referral to primary care, the mean time of diagnosis 
established was at 2.27 months, the shortest term being 3 
weeks, which was confirmed by paraclinical and immuno-
logical tests that require time to perform. Moreover, based 
on the data obtained, the period of diagnosis of the disease 
in recent years has improved due to the high addressability 
of patients in the first 3 months after the disease. The review 
analysis of the literature from the last decades reported that 
the time to establish the diagnosis varies depending on the 
cohort performed, the countries involved in the research 
and the methods of patients' selection. At the same time, the 
results of research in the field do not present similar data 
regarding the time of diagnosis of the disease, thus, the topic 
of the early diagnosis of the disease remains in force [6-9].
The importance of recognizing the initial manifesta-
tions of the disease is indisputable and is explained by the 
researchers’ attempt to further improve the disease classifi-
cation criteria, with increasing their sensitivity and specific-
ity, in order to reduce the time of diagnosis confirmation 
from the onset of the first SLE-related symptom to complete 
clinical diagnosis. However, the disease diagnosis is cur-
rently difficult to establish due to both symptom variety and 
nature of acute to insidious symptom onset. Moreover, the 
signs of the disease may be non-specific and characteristic 
of several medical conditions, which may lead to a delayed 
diagnosis [5-7, 14].
In order to compare the data the present study examined 
some of the important researches on early SLE. Data pub-
lished by Pons Estel B.A. et al. (2004) presented the study 
findings of the Latin American Lupus Study Group research 
(GLADEL), which assessed the manifestations at the on-
set of the disease in the research groups according to race: 
Whites, Mestizo and African-Latin Americans [15]. Thus, 
according to the study findings, the top manifestations at 
onset in the total group of patients with joint involvement 
were recorded in 67.3% of cases, fever – 28.6%, photosen-
sitivity – 24.5%, malarial rash – in 23.6 % and alopecia – in 
20.3% of cases, and total skin disorders – in 46.3% of cases. 
It should be mentioned that the top five manifestations are 
followed by weight loss, nasal / oral ulcers, Raynaud’s syn-
drome and hematological manifestations, which were pres-
ent in more than 10% of cases. Due to the difference in race 
of the total research group, the study aimed to compare the 
frequency of onset manifestations with the cumulative signs 
found within the group of White people. Therefore, the 
most common symptoms were arthralgia and / or arthri-
tis – 93.5%, skin manifestations – 89.5% and fever – 60.2%, 
which is similar to the data from this study, while hemato-
logical manifestations – 68.2%, alopecia – 55.0% and renal 
impairment – 43.6% were detected more frequently in this 
cohort. To note, the frequency of the top manifestations in 
that cohort described was much higher than the data pre-
sented in our study.
The most recent data on early lupus research were pub-
lished in 2018 by M. Mosca [6]. In this study, researchers 
evaluated the manifestations of the disease at the time of 
diagnosis compared with the manifestations of the diseases 
that mimic lupus (Sjogren’s syndrome, antiphospholipid 
syndrome primary, mixed connective tissue disease, sys-
temic sclerosis, rheumatoid arthritis, thyroiditis and auto-
immune hepatitis). Thus, the most common clinical mani-
festations, according to the researchers and appropriate to 
our data were arthritis (57.6%) and alopecia (30.6%), while 
photosensitivity (31.6%) and malar rash (49.6%), which 
were also in the top, in this research cohort showed a higher 
frequency. The important signs of the disease highlighted by 
this cohort study and by M. Mosca were those not included 
in the classification 2012 SLICC criteria. The frequency of 
fever (34.5%) and Raynaud’s syndrome (22.1%) in these 
studies was compliant, whereas the fatigue (28.3%), livedo 
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reticularis (3.1%) and Sjogren’s syndrome (3.9%) prevailed 
within this study. Regarding fatigue, which was one of the 
most important signs of this research paper, it was included 
in the list of the early lupus symptoms only in the study 
conducted by M. Mosca, while in other important studies it 
was omitted [6-9, 15-17].
The study of the laboratory abnormalities, namely he-
matological manifestations showed the highest frequency 
in the early period of leukopenia, which ranged from 5.1% 
in the GLADEL study to 54% in the Europe Inception co-
hort, but also for lymphopenia, noted in these studies in 
5.9% and 45%, respectively, our data being intermediate, 
consisting 29.41% and 16.18%, respectively. Regarding 
thrombocytopenia, it was found in only 5.2% of cases in 
GLADEL and 21% of cases from Europe Inception stud-
ies, respectively, which is more appropriate to our results 
[9, 15]. Thus, as it could be seen the frequency of hema-
tological changes in the early period of lupus varies, how-
ever, the presence of leukopenia and lymphopenia requires 
greater attention. Immunological criteria data highlighted 
a very high frequency of ANA found in most of stud-
ies, similar to our study data. It should be noted that the 
LUMINA study reported only one third of the patients 
with positive ANA [2]. Partial examination of each im-
munological marker revealed the presence of Anti-DNA 
in 71.7% of cases in the study conducted by Mosca and 
78% of cases each in the studies conducted by Rees and 
Sebastiani, while this criterion was more frequenty en-
countered in our study (91%) [6, 7, 9]. The frequency of 
antiphospholipid antibodies did not vary significantly and 
was found in 18.1% and 22% of patients in the Early SLE 
and Europe Inception cohort [7, 9], which corresponds to 
our data.  Another immunological marker, which is part of 
the 1992 ACR criteria, Ac anti-Smith, was determined in 
10% of cases in the Euro-Lupus cohort [16], comparable 
with our data, thus, a higher frequency was noted in the 
Early SLE and Europe Inception studies, 30.2% and 54% 
respectively [6, 9]. Complement analysis as an immuno-
logical criterion for diagnosing the disease was introduced 
only in 2012, thus the previous studies did not determine it. 
Only the Early SLE study determined the frequency of this 
marker in patients with early lupus and established its pre- 
sence in 73.4% of cases while 58.8% of our patients fulfilled 
this criterion [6].
Thus, this present research work might assume that the 
frequency of clinical and paraclinical manifestations in the 
early period of the disease largely varies depending on the 
study performed, the inclusion criteria and the study con-
ducting approach. Disease-specific manifestations, such as 
arthritis / arthralgia, malar rash, photosensitivity and lu-
pus nephritis, as well as nonspecific ones – fever, fatigue 
and Raynaud’s phenomenon, as well as hematological and 
immunological changes show a higher frequency in early 
disease among patients with systemic lupus erythematosus 
and requires a more detailed assessment.
Conclusions
This present study results indicate that top early mani-
festations in SLE patients included in the study were the ar-
thralgia/arthritis, photosensitivity and fatigue, followed by 
malar rash and fever. The mean time of the diagnosis con-
firmation from the first symptom onset that can be referred 
to lupus was 7.08 months.
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